What You Didn't Know About AF and Renal Dysfunction

Percentage of Strokes Attributable to AF Increases With Age

Changes in Kidney Function Over Time

Antithrombotic Therapy in Patients With AF and CKD

Key Pharmacokinetics of NOACs Absorption, Distribution, Metabolism, Excretiona-d

Drug-Drug Interactions With NOACs

NOAC Dosing Considerations for Nonvalvular AF With Renal Adjustments*

Efficacy of Apixaban in Relation to Renal Function in Patient With AF

Subgroup Analysis in ENGAGE AF - TIMI 48 Stroke/SEE by Baseline CrCL*

Ischemic Stroke by CrCl Decile in ENGAGE AF – TIMI 48

Effect of CrCl on Risk for Ischemic Stroke/SEE in ENGAGE AF – TIMI 48 Edoxaban 60 mg vs Warfarin

NOAC Dose Comparisons

EU Label Simulated Dabigatran Treatment

Renal Dysfunction Efficacy and Safety of Apixabana and Dabigatranb With Continuous Analysis of Renal Function

Abbreviations

Abbreviations (cont)

References

References (cont)

References (cont)

References (cont)